Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16061401 | 0.90 | LPAR1 (0.57) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL16060965 | 0.90 | LPAR1 (0.68) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL28613139 | 0.89 | LPAR1 (0.67) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL16060504 | 0.88 | LPAR1 (0.72) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL16060819 | 0.88 | LPAR1 (0.72) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL28599979 | 0.87 | LPAR1 (0.70) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL14711405 | 0.85 | LPAR1 (0.79) | LPAR1LPAR3HRH1 | |
| SCHEMBL11895826 | 0.83 | LPAR1 (0.59) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL14711608 | 0.83 | LPAR1 (0.53) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL14710961 | 0.83 | LPAR1 (0.53) | LPAR1LPAR3ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-2988743-B1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2988743-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014145873-A2 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ABCC3 3255/4885 |
| US-20180297962-A1 | Heterocyclic Compounds Useful In The Treatment of Disease | LPAR1, LPAR4, LPAR2 | LPAR1 1/4885LPAR3 4/4885ABCC3 2420/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | LPAR1 1/4885LPAR3 3/4885ABCC3 2687/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | LPAR1 1/4885LPAR3 3/4885ABCC3 2687/4885 |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR4, LPAR3 | LPAR1 1/4885LPAR3 3/4885ABCC3 2731/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | LPAR1 1/4885LPAR3 3/4885ABCC3 2687/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ABCC3 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.